Project description
Predictive biomarkers for immunotherapy response in B-cell lymphoma
B-cell lymphomas are haematological malignancies originating from B lymphocytes. A promising therapy has recently emerged based on T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19 on B lymphocytes. This redirects the immune system to attack malignant cells. Funded by the Marie Skłodowska-Curie Actions programme, the BEAT B-cell Lymphoma project focuses on the interaction among CART-cells and malignant cells within the tumour microenvironment. The key objective is to discover new biomarkers for real-time feedback on CART therapy response. These biomarkers will help predict outcomes and refine patient selection for clinical trials, ultimately enhancing the efficacy of CART therapy and its effects on patient tissues.
Objective
"Project Title: BEAT B-cell Lymphoma: Biomarkers of Effective CART19 Assessed in Tissue microenvironment
B-cell lymphomas, encompassing Follicular Lymphoma (FL) and Large B-cell Lymphoma (LBCL), pose significant health concerns. While the use of T-cells modified with a chimeric antigen receptor targeting CD19 (CART19) offers a potential breakthrough in treating these malignancies, it is imperative to unravel the intricate dynamics between the CART19 and the tumor B-cells within their unique tissue microenvironment (TME).
The ""BEAT B-cell Lymphoma"" initiative is poised to transform lymphoma therapeutic strategies. More than just advancing the status quo, this project is geared towards unveiling novel biomarkers that facilitate immediate feedback on therapeutic outcomes. These newfound markers will empower clinicians and patients with predictive tools for CART19 interventions and serve as cornerstones for redefining inclusion criteria in subsequent clinical trials. But the ambition of this endeavor goes beyond mere biomarker discovery. It promises in-depth revelations on how CART19 impacts actual patient-derived tissues, deepening our knowledge and inspiring fresh treatment avenues. The short term concrete vision? Fine-tuning CART19's performance and honing the initial patient selection process.
As a medical doctor with a specialization in hematopathology, I've offered numerous diagnoses of B-cell lymphomas, grounded in histological and molecular markers predominantly sourced from tumor B-cells. My foundational training as an immunologist has sharpened my curiosity, drawing my attention to the often underemphasized tissue microenvironment. My affinity for bioinformatics further equips me to navigate and interpret vast datasets efficiently. To ensure the success of this project and to further my journey towards becoming an independent researcher, I partnered with the renowned Alizadeh Lab at Stanford, USA and will later join the de Miranda lab in the Netherlands."
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-TMA-MSCA-PF-GF - HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-MSCA-2023-PF-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2333 ZA Leiden
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.